PAINREFORM LTD.

Painreform Ltd.

Drug Manufacturers - Specialty & Generic Healthcare Tel Aviv, Israel PRFX (NCM)

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Other Drug Manufacturers - Specialty & Generic Companies

View All →

Frequently Asked Questions

Has PAINREFORM LTD. had layoffs?
No layoff events have been recorded for PAINREFORM LTD. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does PAINREFORM LTD. have?
PAINREFORM LTD. has approximately 2 employees.
What industry is PAINREFORM LTD. in?
PAINREFORM LTD. operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
Is PAINREFORM LTD. a publicly traded company?
Yes, PAINREFORM LTD. is publicly traded under the ticker symbol PRFX on the NCM. The company has a market capitalization of approximately $0.00 billion.
Where is PAINREFORM LTD. headquartered?
PAINREFORM LTD. is headquartered in Tel Aviv, Israel at 65 Yigal Alon St., Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.